SCHEMBL20113783

SCHEMBL20113783

COc1cccc(-c2ccc(=O)n(C(C)C(=O)Nc3cccc(C(C)(C)C)c3)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.54
TP53 P04637 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 5/20 0.46
POLB P06746 5/20 0.46
FYN P06241 1/20 0.45
THRB P10828 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
FPR1 P21462 1/20 0.44
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
STAT1 P42224 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20114214 0.92 MAPT (0.54) MAPTTP53L3MBTL1LMNAPOLB
SCHEMBL20113785 0.92 TP53 (0.56) MAPTTP53LMNAPOLBTHRB
SCHEMBL20114212 0.91 MAPT (0.61) MAPTTP53L3MBTL1LMNAPOLB
SCHEMBL20113789 0.88 TP53 (0.64) MAPTTP53L3MBTL1LMNAPOLB
SCHEMBL20113849 0.88 MAPT (0.47) MAPTTP53LMNAPOLBFYN
SCHEMBL20113798 0.87 MAPT (0.52) MAPTTP53L3MBTL1LMNAPOLB
SCHEMBL20113788 0.87 POLB (0.56) MAPTTP53L3MBTL1LMNAPOLB
SCHEMBL20113830 0.86 MAPT (0.49) MAPTTP53L3MBTL1LMNAPOLB
SCHEMBL20113831 0.85 TP53 (0.56) MAPTTP53LMNAPOLBTHRB
SCHEMBL20113799 0.85 MAPT (0.62) MAPTTP53L3MBTL1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. 2019-08-22 US disclosed
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. 2019-08-22 US disclosed
WO-2018081377-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256474-A1 N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS CFTR, PKD2, CLCN2 MAPT 4874/4885TP53 2421/4885L3MBTL1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.